About the Authors
- Matthieu Dusselier
-
Roles Conceptualization, Investigation, Writing – original draft
* E-mail: matthieu.dusselier@gmail.com
Affiliation Service de Pneumologie, CHU, Limoges, France
- Elise Deluche
-
Roles Project administration
Affiliation Service d’Oncologie Médicale, CHU, Limoges, France
- Nellie Delacourt
-
Roles Writing – review & editing
Affiliation Service de Pneumologie, CHU, Limoges, France
- Julia Ballouhey
-
Roles Writing – review & editing
Affiliation Service de Pneumologie, CHU, Limoges, France
- Thomas Egenod
-
Roles Resources
Affiliation Service de Pneumologie, CHU, Limoges, France
- Boris Melloni
-
Roles Writing – review & editing
Affiliation Service de Pneumologie, CHU, Limoges, France
- Charlotte Vergnenègre
-
Roles Resources, Writing – review & editing
Affiliation CHU Bordeaux, service des maladies respiratoires, Bordeaux, France
- Rémi Veillon
-
Roles Resources
Affiliation CHU Bordeaux, service des maladies respiratoires, Bordeaux, France
- Alain Vergnenègre
-
Roles Investigation, Supervision
Affiliation Service de Pneumologie, CHU, Limoges, France
Competing Interests
The authors have read the journal’s policy and the authors of this manuscript have the following competing interests: TE is a paid advisory board member for Bristol-Myers Squibb, Merck-Sharp and Dohme, and Hoffmann-La Roche. RV is a paid expert for Bristol-Myers Squibb and Merck-Sharp and Dohme. He received honoraria from Bristol-Myers Squibb, and Merck-Sharp and Dohme for consultancy and board membership, and received reimbursement for congress registration from Bristol-Myers Squibb and Merck-Sharp and Dohme outside the present study. AV is a paid expert board member for Bristol-Myers Squibb, Merck-Sharp and Dohme, and Hoffmann-La Roche. He received honoraria from Bristol-Myers Squibb, Merck-Sharp and Dohme, Hoffmann-La Roche, Pierre Fabre Oncologie, and AstraZeneca for consultancy and board membership. AV also received reimbursement for congress registration from Pierre Fabre Oncologie and AstraZeneca outside the present study. There are no patents, products in development or marketed products associated with this research to declare. This does not alter our adherence to PLOS ONE policies on sharing data and materials.